Although the contribution of SG in PERK-mediated tumor growth and angiogenesis remained to be established, our study described here suggests the formation of SG as a potential downstream effector of PERK in Lap resistance, an assumption that requires future in vivo studies using patient-derived xenografts and breast biopsies of cancer patients, to be validated. The gene discussed is EIF2AK3; the disease is cancer.